44
Welcome to the Brand page for “44”, which is offered here for The mark consists of the 44 text inside of a partially full circle a top of a boat with 2 parallel wavy lines with one longer than the other at the bottom of the boat.;oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders;forty four; four four;color is not claimed as a feature of the mark.;conducting clinical trials in the fields of pharmaceuticals and biotechnology, conducting clinical trials for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; medical and scientific research, conducting clinical trials for oligonucleotide-based therapeutics;.
Its status is currently believed to be active. Its class is unavailable. “44” is believed to be currently owned by “Avidity Biosciences, Inc.”
| Owner: |
AVIDITY BIOSCIENCES, INC.
Owner Details |
|---|---|
| Description: |
The mark consists of the 44 text inside of a partially full circle a top of a boat with 2 parallel wavy lines with one longer than the other at the bottom of the boat.;oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders;FORTY FOUR; FOUR FOUR;Color is not claimed as a feature of the mark.;conducting clinical trials in the fields of pharmaceuticals and biotechnology, conducting clinical trials for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; medical and scientific research, conducting clinical trials for oligonucleotide-based therapeutics;
|
| Categories: |
